company background image
9969 logo

InnoCare Pharma SHSC:9969 Stock Report

Last Price

HK$6.67

Market Cap

HK$14.2b

7D

6.9%

1Y

7.4%

Updated

02 Dec, 2024

Data

Company Financials +

InnoCare Pharma Limited

SHSC:9969 Stock Report

Market Cap: HK$14.2b

9969 Stock Overview

A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. More details

9969 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

InnoCare Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for InnoCare Pharma
Historical stock prices
Current Share PriceHK$6.67
52 Week HighHK$7.92
52 Week LowHK$4.03
Beta1.02
11 Month Change1.37%
3 Month Change30.02%
1 Year Change7.41%
33 Year Change-63.31%
5 Year Changen/a
Change since IPO-50.74%

Recent News & Updates

Recent updates

Shareholder Returns

9969HK BiotechsHK Market
7D6.9%2.5%1.4%
1Y7.4%-7.5%14.9%

Return vs Industry: 9969 exceeded the Hong Kong Biotechs industry which returned -12.4% over the past year.

Return vs Market: 9969 underperformed the Hong Kong Market which returned 13.1% over the past year.

Price Volatility

Is 9969's price volatile compared to industry and market?
9969 volatility
9969 Average Weekly Movement9.2%
Biotechs Industry Average Movement10.9%
Market Average Movement8.9%
10% most volatile stocks in HK Market19.0%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 9969 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 9969's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20151,109Jasmine Cuiwww.innocarepharma.com

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.

InnoCare Pharma Limited Fundamentals Summary

How do InnoCare Pharma's earnings and revenue compare to its market cap?
9969 fundamental statistics
Market capHK$14.21b
Earnings (TTM)-HK$401.72m
Revenue (TTM)HK$961.68m

12.2x

P/S Ratio

-29.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9969 income statement (TTM)
RevenueCN¥898.92m
Cost of RevenueCN¥125.58m
Gross ProfitCN¥773.34m
Other ExpensesCN¥1.15b
Earnings-CN¥375.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin86.03%
Net Profit Margin-41.77%
Debt/Equity Ratio20.9%

How did 9969 perform over the long term?

See historical performance and comparison